Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more
Leap Therapeutics Inc (LPTX) - Net Assets
Latest net assets as of September 2025: $2.69 Million USD
Based on the latest financial reports, Leap Therapeutics Inc (LPTX) has net assets worth $2.69 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.40 Million) and total liabilities ($8.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.69 Million |
| % of Total Assets | 23.64% |
| Annual Growth Rate | 8.55% |
| 5-Year Change | -48.0% |
| 10-Year Change | 30.44% |
| Growth Volatility | 74.95 |
Leap Therapeutics Inc - Net Assets Trend (2012–2024)
This chart illustrates how Leap Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Leap Therapeutics Inc (2012–2024)
The table below shows the annual net assets of Leap Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $35.05 Million | -41.72% |
| 2023-12-31 | $60.14 Million | +10.06% |
| 2022-12-31 | $54.64 Million | -49.35% |
| 2021-12-31 | $107.89 Million | +60.06% |
| 2020-12-31 | $67.41 Million | +3953.97% |
| 2019-12-31 | $-1.75 Million | -119.06% |
| 2018-12-31 | $9.18 Million | -17.47% |
| 2017-12-31 | $11.12 Million | -- |
| 2016-12-31 | $0.00 | -- |
| 2015-12-31 | $26.87 Million | -41.85% |
| 2014-12-31 | $46.21 Million | +146.24% |
| 2013-12-31 | $18.77 Million | +43.30% |
| 2012-12-31 | $13.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Leap Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44294800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $38.00K | 0.11% |
| Other Comprehensive Income | $-120.00K | -0.34% |
| Other Components | $502.50 Million | 1433.75% |
| Total Equity | $35.05 Million | 100.00% |
Leap Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Leap Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Feature Integration Technology Inc.
TWO:4951
|
$62.33 Million |
|
WM Technology Inc
NASDAQ:MAPS
|
$62.33 Million |
|
OUE Limited
F:OUE1
|
$62.34 Million |
|
Ffbw Inc
OTCQX:FFBW
|
$62.34 Million |
|
Groupe Pizzorno Environnement SA
PA:GPE
|
$62.31 Million |
|
Mewah International Inc
F:MWX
|
$62.31 Million |
|
Calisa Acquisition Corp Ordinary shares
NASDAQ:ALIS
|
$62.29 Million |
|
Waratah Minerals Ltd
AU:WTM
|
$62.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Leap Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 60,141,000 to 35,048,000, a change of -25,093,000 (-41.7%).
- Net loss of 67,555,000 reduced equity.
- Dividend payments of 234,000 reduced retained earnings.
- New share issuances of 39,999,000 increased equity.
- Other comprehensive income decreased equity by 226,000.
- Other factors increased equity by 2,923,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-67.56 Million | -192.75% |
| Dividends Paid | $234.00K | -0.67% |
| Share Issuances | $40.00 Million | +114.13% |
| Other Comprehensive Income | $-226.00K | -0.64% |
| Other Changes | $2.92 Million | +8.34% |
| Total Change | $- | -41.72% |
Book Value vs Market Value Analysis
This analysis compares Leap Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.12x to 2.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $17.59 | $2.05 | x |
| 2013-12-31 | $25.21 | $2.05 | x |
| 2014-12-31 | $38.95 | $2.05 | x |
| 2015-12-31 | $15.75 | $2.05 | x |
| 2016-12-31 | $-106.71 | $2.05 | x |
| 2017-12-31 | $12.10 | $2.05 | x |
| 2018-12-31 | $6.37 | $2.05 | x |
| 2019-12-31 | $-0.77 | $2.05 | x |
| 2020-12-31 | $11.36 | $2.05 | x |
| 2021-12-31 | $12.57 | $2.05 | x |
| 2022-12-31 | $4.83 | $2.05 | x |
| 2023-12-31 | $2.94 | $2.05 | x |
| 2024-12-31 | $0.93 | $2.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Leap Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -192.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-192.75%) is below the historical average (-98.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -59.22% | 0.00% | 0.00x | 1.35x | $-9.07 Million |
| 2013 | -97.64% | 0.00% | 0.00x | 1.11x | $-20.20 Million |
| 2014 | -55.08% | 0.00% | 0.00x | 1.05x | $-30.07 Million |
| 2015 | -78.54% | 0.00% | 0.00x | 1.05x | $-23.79 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.61 Million |
| 2017 | -267.40% | 0.00% | 0.00x | 2.61x | $-30.84 Million |
| 2018 | -252.19% | 0.00% | 0.00x | 2.08x | $-24.06 Million |
| 2019 | 0.00% | -8773.33% | 0.05x | 0.00x | $-32.73 Million |
| 2020 | -5.02% | -33.69% | 0.14x | 1.04x | $-10.13 Million |
| 2021 | -37.62% | -2705.80% | 0.01x | 1.09x | $-51.38 Million |
| 2022 | -99.92% | -14558.93% | 0.01x | 1.06x | $-60.06 Million |
| 2023 | -135.37% | 0.00% | 0.00x | 1.21x | $-87.43 Million |
| 2024 | -192.75% | 0.00% | 0.00x | 1.40x | $-71.06 Million |
Industry Comparison
This section compares Leap Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Leap Therapeutics Inc (LPTX) | $2.69 Million | -59.22% | 3.23x | $62.33 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |